Wednesday, April 05, 2023
Scorpion Therapeutics and Pierre Fabre announced an exclusive collaboration and licence agreement for the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor (“EGFR”) inhibitors.
Under the agreement, Scorpion will lead clinical development of STX-721 and Pierre Fabre will lead clinical development of STX-241. Scorpion will retain commercialisation rights to STX-721 and STX-241 in the United States, Canada and Japan, and Pierre Fabre will be responsible for commercialisation activities in all other territories, with a focus on Europe and China.
Based on the preclinical data, that STX-721 and STX-241 will present best-in-class product profiles. Further, this partnership will significantly expand efforts in precision oncology, to better support the care and treatment of thousands of people globally.